The protective immunity conferred by a set of recombinant vaccinia viruses containing the entire coding sequence of dengue virus type 4 nonstructural glycoprotein NS1 plus various flanking sequences was evaluated by using a mouse encephalitis model. Mice immunized with recombinant vNS1-NS2a, which expresses authentic NS1, were solidly protected against intracerebral dengue virus challenge. However, mice immunized with recombinants vNS1-15%NS2a and vRSVG/NS1-15%NS2a, which express aberrant forms of NS1, were only partially protected (63 to 67% survival rate). Serologic analysis showed that mice immunized with vNS1-NS2a developed high titers of antibodies to NS1 as measured by radioimmunoprecipitation, enzymelinked immunosorbent assay, and complement-mediated cytolytic assays. In addition, a pool of sera from these animals was protective in a passive transfer experiment. Lower titers of NS1-specific antibodies were detected in sera of animals immunized with vNS1-15%NS2a or vRSVG/NSl-15%NS2a by all three assays. These data support the view that protection against dengue virus infection in mice may be mediated at least in part by NS1-specific antibodies through a mechanism of complement-mediated lysis of infected cells. Additionally, immunization with two recombinant viruses expressing authentic NS1 of dengue virus type 2 conferred partial protection (30-50%) against dengue virus type 2 challenge.
Dengue virus poses a major threat to the public health, causing epidemics throughout tropical areas worldwide. The four serotypes of dengue virus constitute a subgroup of the flavivirus family. Many other flaviviruses are also causative agents of human disease, for example, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. These viruses are transmitted by tick or mosquito vectors; dengue virus is transmitted by mosquitoes of the genus Aedes. An estimated 100 million cases of dengue illness occur each year (10) . Dengue virus predominantly causes a debilitating illness known as dengue fever. Occasionally, the more serious dengue hemorrhagic fever-shock syndrome results. This severe disease is most common in young children and has a high mortality rate. Following recovery from dengue virus infection, immunity to the infecting serotype (homotypic immunity) is apparently lifelong (21, 24) ; this makes dengue virus a good candidate for immunoprophylaxis. However, despite over 40 years of effort, safe and effective dengue virus vaccines are not available. Control of flaviviruses, particularly dengue virus, is a global concern; the World Health Organization has designated dengue virus as one of five high-priority targets for vaccine development.
Humans recovering from dengue illness, especially from secondary dengue virus infections, have high titers of antibodies to nonstructural glycoprotein NS1 and to the dengue viral structural proteins, particularly the envelope (E) glycoprotein, in their sera (19, 23, 29) . Antibody to E neutralizes dengue virus in vitro, and inoculation of mice with a monoclonal antibody (MAb) to E can protect against subsequent intracerebral homotypic dengue virus challenge (18) . NS1 is important in protection also, since mice immunized with * Corresponding author. purified NS1 protein (28) or inoculated with specific combinations of MAbs to NS1 (15) are protected. Protection by antibodies to NS1 is thought to involve immune recognition of NS1 at the infected-cell surface, followed by complementmediated lysis (27, 28) .
Recombinant vaccinia viruses expressing protective antigens have been tested as a vaccine strategy against a wide variety of viruses. We have recently constructed several vaccinia viruses that express E of dengue virus type 4 (DEN4), and immunization of mice with these recombinants induced resistance to dengue virus encephalitis (1, 2). However, this is legitimate concern about using E as an immunogen in humans. Antibodies to E can enhance replication of dengue virus in cells of the monocyte-macrophage lineage in vitro (11) (12) (13) . This enhanced replication is thought to result from increased entry of virus-antibody complexes into cells bearing Fc receptors. This mechanism of immune enhancement of viral replication is thought to be a contributing factor in the etiology of dengue hemorrhagic fever-shock syndrome, in view of the correlation of severe disease and the presence of preexisting antibody in children, either from prior heterotypic infection or from passive transfer from a dengue virus-immune mother (reviewed in reference 10) . Immunization with NS1 is an attractive possibility, since NS1 is not part of the virion, and immune enhancement can be avoided. We recently described a series of recombinant vaccinia viruses that contain the NS1 sequence of DEN4 plus various lengths of the downstream gene NS2a, with or without the upstream genes coding for capsid (C), premembrane (preM), and E (7) . Recombinants that contain all of NS2a apparently express authentic NS1, whereas those that contain less than half of NS2a express an uncleaved NS1-NS2a product. In this report, we describe the construction of two additional recombinant vaccinia viruses that express were used as negative controls in the mouse protection studies (see below). Vaccinia virus recombinants vC-M-E-NS1-NS2a, vC-M-E-NS1-15%NS2a, vNS1-NS2a, and vNS1-15%NS2a have already been described (7, 33) , as has recombinant vC-M-E (2). Recombinant vRSVGINS1-15% NS2a was made from plasmid pSC11/4INSlC (7) as previously described (6) . Recombinants vDEN2(2041-4497) and vDEN2(2304-4497) were made from plasmids pSC11/DEN2 (2041-4497) and pSC11/DEN2(2304-4497), which are described in the next section. Small-scale stocks of recombinant viruses were grown on CV-1 cells. Large-scale stocks were grown in HeLa cells, and virus was purified by sucrose gradient centrifugation as previously described (17) . Virus stock titers were determined on CV-1 cells. HMAF 1 day before challenge with DEN4 at 6 weeks of age as described above.
Analysis of mouse sera. Three methods were used to analyze mouse sera for anti-dengue virus antibodies: immune precipitation, enzyme-linked immunosorbent assay (ELISA), and complement-mediated immune cytolysis. For immune precipitations, 20 ,ul of "S-labeled proteins from DEN4-infected cells were precipitated by 5 ,ul of mouse serum or 1 ,ul of DEN4 HMAF as a positive control for at least 2 h on ice. Collection of immune complexes by using Pansorbin, washing, solubilization, and SDS-gel electrophoresis was done as previously described (7).
A standard ELISA protocol, which included use of Immulon 1 U plates (Dynatech Laboratories, Inc., Alexandria, Va.), was used. The antigen in the solid phase was DEN4 814699-infected cell lysate, and the second antibody was peroxidase-conjugated goat anti-mouse immunoglobulin G (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, Md.). Sera were diluted from 1:10 to 1:640 in twofold steps. Positive samples were those whose A590 values exceeded twice the average A590 value for the 1:10 dilutions of the negative control sera from mice immunized with vPE11. The titer of a serum was the reciprocal of the last dilution that gave a positive result. Samples that were negative at 1:10 were assumed to contain no antibodies to NS1. Some samples had very high A5g values at 1:640; these were assigned a titer of 1:1,280 for calculation of group averages. This was likely an underestimate of the titers of these samples.
A modified complement-mediated cytolytic assay was performed to determine the cytolytic activity of pooled postimmunization mouse sera (26, 27) . Briefly, target human adenocarcinoma SW13 cells grown to confluence in 96-well microtest plates were infected with DEN4 H241 and labeled with Na251CrO4 at 48 h postinfection, at which time cells were uniformly infected as determined by immunofluorescence assay. Labeled infected monolayers were incubated at 37°C for 2 h with heat-inactivated serum and rabbit complement (1:20) before being harvested with a Titertek supernatant collection system. Assays were performed in quadruplicate, and percent lysis was calculated by using the following formula: (experimental 51Cr release -spontaneous release) x 100/(maximal release -spontaneous release). Spontaneous release was determined with serum and heat-inactivated complement, and maximal release was the value obtained after detergent lysis of the cell monolayer with 1% Nonidet P-40. As a positive control, rabbit antiserum specific for DEN2 NS1 (28) was used. Samples which had percent lysis values that exceeded twice the value obtained with negative control sera were considered positive. The titer of a sample was the reciprocal of the last dilution which was positive. RESULTS Analysis of protein expression by recombinant vaccinia viruses. The structures of the polyproteins encoded by the recombinant vaccinia viruses containing DEN4 cDNA are shown in Fig. la . Viruses vC-M-E, vC-M-E-NS1-NS2a, vC-M-E-NS1-15%NS2a, vNSl-NS2a, and vNS1-15%NS2a have been described previously (2, 7, 33). Cells infected with vC-M-E-NS1-NS2a expressed preM, E, and NS1 proteins that comigrated on SDS-polyacrylamide gels with the authentic proteins from DEN4-infected cells (33; data not shown). Expression of C and NS2a was not detected. Similarly, cells infected with vC-M-E expressed preM and E that comigrated with DEN4 proteins, but expression of C was not detected (2). Recombinant vC-M-E-NS1-15% NS2a directed expression of authentic preM and E proteins, but (15) a On the basis of standard chi-square analysis for pairwise compansons, each of the first five viruses is significantly different from the negative control group (P < 0.0005). The vNS1-15%NS2a (P < 0.005) and vRSVG/NS1-15%NS2a (P < 0.0005) groups are each significantly different from vNS1-NS2a, but they are not significantly different from each other.
b The data represent the pooled results of five independent experiments. Some of the data from individual experiments have been presented previously as parts of other sets of pooled data (1, 2). expression of C was not seen (7; data not shown). In addition, cleavage between NS1 and NS2a did not occur, which resulted in an NS1-NS2a fusion product (NS1x) that was larger than the authentic protein (7; see below). The DEN4-specific proteins expressed by cells infected with vNSl-NS2a, vNS1-15%NS2a, or vRSVG/NS1-15%NS2a are shown in Fig. lb . As reported previously (7) , vNS1-NS2a directed expression of NS1 of authentic size, which appeared in the gel as a cluster of bands. Cells infected by vNS1-15%NS2a produced an NS1 species (NS1l) larger than authentic NS1. NS1x results from failure to cleave between NS1 and NS2a, and this protein presumably consists of NS1 plus the N-terminal 32 amino acids of NS2a plus 5 vectorencoded residues. Recombinant vRSVG/NS1-15%NS2a is similar to vNS1-15%NS2a, but the 24-residue DEN4 NS1 signal sequence is replaced by the 71 N-terminal amino acids of the respiratory syncytial virus G glycoprotein, which acts as a signal but is not cleaved (25, 31, 32) . Cells infected with vRSVG/NS1-15%NS2a expressed an even larger NS1 species (RSVG/NS1x), as expected, since this product should contain the 71-amino-acid respiratory syncytial virus G glycoprotein sequence at the N terminus in addition to the uncleaved NS2a residues at the C terminus. The reduced intensities of the NSlx and RSVG/NSlx bands compared with NS1 presumably were due to decreased stability or decreased reactivity with the polyclonal antiserum used for immunoprecipitation.
Protective immunity of DEN4 NS1 expressed by recombinant vaccinia viruses. It has been established that dengue virus NS1 is a protective antigen, since immunization of mice with purified NS1 of DEN2 induces resistance to dengue encephalitis (28 cephalitis and 94% of that group survived challenge. Additionally, 15 mice that received recombinant vC-M-E-NS1-15%NS2a were fully protected. It was shown previously that immunization with a vaccinia virus recombinant expressing only E is completely protective (1, 2). Since vC-M-E-NS1-NS2a and vC-M-E-NS1-15%NS2a express E, it was not surprising to find that these viruses also induced solid protection against dengue virus challenge.
To assess the role that NS1 might play in protection of mice from encephalitis, recombinants vNS1-NS2a, vNS1-15%NS2a, and vRSVG/NS1-15%NS2a were evaluated for protective efficacy. All mice immunized with vNS1-NS2a survived DEN4 challenge (Table 1 Fig. 2 ; results for sera from animals immunized with other recombinants are not shown (but see reference 2).
Sera from animals immunized with vC-M-E-NS1-NS2a or vNS1-NS2a had similar levels of NS1-specific antibodies, as measured by the similar intensities of labeled NS1 precipitated by these sera. Antibodies specific to other DEN4 proteins were not detected in any sera (also see reference 2). survived challenge also had low levels of NS1-specific antibodies. In contrast, antibodies to NS1 were not detected in most sera from mice immunized with either vC-M-E-NS1-15%NS2a or vNS1-15%NS2a. The few positive sera from these mice had barely detectable levels of NS1-specific antibodies. Immunoprecipitation also failed to detect NS1-specific antibodies in sera from mice immunized with either vRSVG71/NS1-15%NS2a or negative control viruses. Several serum samples collected from mice that had survived for 21 days postchallenge were also analyzed. Greatly increased levels of NS1-specific antibodies were present in these sera (Fig. 2) , as expected for animals that had been inoculated with challenge virus.
Additional analysis of the seroresponse to NS1 before challenge was performed by using ELISA. Forty-eight individual sera were assayed, eight each from groups of mice that had been immunized with vPE11, vC-M-E-NS1-NS2a, vC-M-E-NS1-15%NS2a, vNS1-NS2a, vNS1-15%NS2a, or vRSVG/NS1-15%NS2a. Serial dilutions of sera were incubated with DEN4-infected-cell lysate in the solid phase, and peroxidase-conjugated goat anti-mouse immunoglobulin G was used as the second antibody. Sera from animals immunized with vC-M-E-NS1-NS2a or vNS1-NS2a had the highest mean titers, a finding which was in agreement with the immunoprecipitation results. It was shown previously that animals immunized with vC-M-E-NS1-NS2a developed a low or undetectable level of virion-specific antibodies as measured by ELISA (2). Furthermore, the group average titer of sera from mice immunized with vC-M-E-NS1-15%NS2a was less than 5% of the average for the vC-M-E-NS1-NS2a-immunized group. Also, the mean ELISA titer of sera from the vC-M-E-NS1-15%NS2a group was not higher than the mean titer of sera from the vNS1-15%NS2a group (Fig. 3) . Taken shown and also from mice immunized with vPE11 to serve as the negative control. Eight serum samples from each group were assayed by ELISA by using DEN4-infected cell lysate as the antigen. The ELISA titer is the reciprocal of the highest dilution of a sample which was positive. Samples which were negative at a 1:10 dilution are shown as having a titer of <10 and were assumed to contain no antibodies to NS1. Samples with very high A590 values at a 1:640 dilution are shown as having a titer of >640; these samples were assigned a titer of 1,280 for calculation of the geometric mean titer.
To demonstrate that antibodies to NS1 in serum were responsible for protection against dengue encephalitis, we performed passive transfer experiments. Unimmunized recipient mice were inoculated with pooled postimmunization sera from donor mice that had been immunized with vNS1-NS2a or vSC8. The recipients were challenged with DEN4 1 day later and observed for 21 days for symptoms of dengue encephalitis. Mice inoculated with DEN4 hyperimmune mouse ascitic fluid or sera from vNS1-NS2a-immunized animals exhibited significant resistance to challenge compared with mice inoculated with phosphate-buffered saline or sera from mice immunized with vSC8 (Table 2 ). These observations indicate that humoral immunity played a role in the resistance induced by immunization with NS1. In mice immunized with vNS1-NS2a, it is likely that antibodies against NS1 were responsible for the protection observed.
Protection of mice against DEN2. Two recombinant viruses that contain DEN2 sequences, vDEN2(2041-4497) and vDEN2(2304-4497) (Fig. 4a) , were constructed for expression of authentic DEN2 NS1 and for evaluation of their protective efficacies in mice. Both viruses encode all of NS1 and NS2a and the N-terminal 84% of NS2b, but they differ in the extent of E sequences present. vDEN2(2041-4497) is PROTECTIVE IMMUNITY ELICITED BY DENGUE VIRUS NS1 a The inverse of the last serum dilution which was positive in the complement-mediated cytolysis assay is shown. ND, Not determined. <10, The 1:10 dilution (the least dilute sample tested) was negative. b p < 0.005, comparing vNS1-NS2a with vSC8 by standard chi-square analysis.
c The average of separate titrations of serum pools from mice which survived challenge and from mice that died, each of which had a titer of 40, is shown.
d The average of separate titrations of serum pools from mice which survived challenge (titer, 20) and from mice that died (titer, 80) is shown.
eDEN4 HMAF was used as a positive control for the passive transfer experiment.
f PBS, Phosphate-buffered saline, was used as a negative control for the passive transfer experiment.
residues of E, including the 39 C-terminal residues, which are composed of two blocks of hydrophobic amino acids (14 and 24 residues long) separated by a single arginine. These hydrophobic blocks are thought to act as a stop transfer signal for E and as a signal sequence for NS1. The predicted polyprotein of vDEN2(2304-4497) contains only the 39 Cterminal amino acids of E. The DEN2-specific proteins produced in cells infected by these two recombinants are shown in Fig. 4b (28) and MAbs to NS1 (15) (20) . Although these animals developed NS1-specific antibodies after immunization, the levels were low and the duration and peak titers of dengue viremia in these monkeys were similar to those of unimmunized controls. It is possible that the level of dengue virus proteins expressed by vC-M-E-NS1-NS2a was insufficient to induce a protective response in monkeys. Perhaps a second generation of recombinant vaccinia viruses which express larger amounts of protective antigens would result in improved immunogenicity and protective efficacy in monkeys.
